Maybe. Tasigna and Sprycel have shown statsig superiority to Gleevec in the first-line setting, but the CML market has proven to be sticky—see #msg-65404601.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”